Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

The Dow traded up 0.35% to 33,178.65 while the NASDAQ rose 0.01% to 12,537.98. The S&P also rose, gaining, 0.54% to 4,177.90.

Also check this: Executives Buy Around $1.6M Of 4 Penny Stocks

Leading and Lagging Sectors

Energy shares climbed 2.5% on Tuesday. Meanwhile, top gainers in the sector included TETRA Technologies, Inc. (NYSE:TTI), up 16% and CVR Energy, Inc. (NYSE:CVI) up 13%.

In trading on Tuesday, consumer discretionary shares fell by 0.2%.

Top Headline

Pfizer Inc. (NYSE:PFE) posted upbeat results for its first quarter on Tuesday.

Pfizer posted quarterly adjusted earnings of $1.62 per share, exceeding analysts’ estimates of $1.50 per share. The company’s quarterly sales came in at $25.70 billion, versus expectations of $23.95 billion.

Pfizer revised its FY22 adjusted EPS guidance to $6.25-$6.45 to reflect $0.11 negative impact for accounting policy change. The company also sees sales of $98 billion to $102 billion.

Equities Trading UP

Belite Bio, Inc (NASDAQ:BLTE) shares shot up 28% to $11.39. The FDA has granted Fast Track Designation to Belite Bio’s LBS-008 for Stargardt disease (STGD1).

Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) got a boost, shooting 33% to $3.5316 after the company and its partner MicroSafe Group DMCC received EPA approval for Nanocyn as a hospital-grade disinfectant.

Enovix Corporation (NASDAQ:ENVX) shares were also up, gaining 21% to $10.83. Enovix announced initial smartwatch battery order from leading global consumer electronics company.

Equities Trading DOWN

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares tumbled 60% to $2.0180. Spero Therapeutics will defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting (LCM) with the FDA.

Shares of Chegg, Inc. (NYSE:CHGG) were down 30% to $17.48 after the company reported Q1 earnings results and issued Q2 and FY22 sales guidance below analyst estimates.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) was down, falling 26% to $24.13 after the company reported worse-than-expected Q1 EPS and sales results.

Also check out: 4 Stocks Under $3 Insiders Are Aggressively Buying


In commodity news, oil traded down 0.8% to $104.29, while gold traded up 0.6% to $1,874.80.

Silver traded up 1% Tuesday to $22.815 while copper rose 0.5% to $4.2895.

Euro zone

European shares were mostly higher today. The eurozone’s STOXX 600 gained 0.28%, London’s FTSE 100 fell 0.05% and Spain’s IBEX 35 Index rose 1.62%. The German DAX gained 0.26%, French CAC 40 gained 0.40% and Italy’s FTSE MIB Index climbed 1.33%.

The unemployment rate in the Eurozone dropped to a record low of 6.8% in March from a revised 6.9% in February, while annual producer inflation rose to record high of 36.8% in March from a revised 31.5 percent in February. UK’s manufacturing PMI increased to 55.8 in April from a preliminary of 55.3, while unemployment rate in Germany remained at 5%.


The Federal Open Market Committee will begin its two-day policy meeting today.

Factory orders rose 2.2% month-over-month to $557.3 billion in March.

The number of job openings increased by 205,000 from a month ago to a series high of 11.549 million in March.

Check out this: Executives Buy More Than $90M Of 4 Stocks

COVID-19 Update

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 83,170,400 cases with around 1,021,080 deaths. India confirmed a total of at least 43,085,160 cases and 523,880 deaths, while Brazil reported over 30,460,990 COVID-19 cases with 663,650 deaths. In total, there were at least 514,034,340 cases of COVID-19 worldwide with more than 6,263,580 deaths.

Related Posts
Read More

CymaBay Therapeutics Announced Collaboration with Kaken Pharmaceutical to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis; Kaken to Make Upfront Payment To Cymabay Of ~$34M Plus Milestone Payments Up To ~$128.4M And Royal…

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis ("PBC").